RBC Capital Out Negative on Gilead Sciences (GILD), 'see the stock as lacking'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to RBC Capital Out Negative on Gilead Sciences (GILD), 'see the stock as lacking'
January 22, 2024 8:47 AM EST
AstraZeneca (NASDAQ: AZN) Gains After Gilead Sciences (NASDAQ: GILD) Study in Lung Cancer Fails
GILD -9%AZN +3% Gilead Sciences, Inc. (Nasdaq:
GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in...
More
January 22, 2024 8:42 AM EST
Gilead Sciences Sinks 11% After Lung Cancer Study Fails
A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology. The safety profile for Trodelvy was consistent with prior studies. Trodelvy was generally well tolerated, and no new safety signals...
More
January 22, 2024 8:30 AM EST
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology. The safety profile for Trodelvy was consistent with prior studies. Trodelvy was... More
